drugset / Trial / NCT06833411

Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone

NCT06833411

Phase 3 Not yet recruiting 178 enrolled Insel Gruppe AG, University Hospital Bern
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The GISCO study plans to determine whether 8-week therapy is just as effective as 26-week cortisone therapy for treating giant cell arteritis * with tocilizumab, * while using less cortisone.

Timeline

Start
2026-07
Primary completion
2030-08
Completion
2032-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prednisone Other / unclassified

Indications